Norwegian Health Authority conducts a clinical trial of Feasibility of Remote Assessment of the Jugular Venous Pressure

Eastern Regional Health Authority is starting a new clinical trial of Feasibility of Remote Assessment of the Jugular Venous Pressure.

JVPLabs is the collaborator in this study.

CHF is a common and devastating health problem estimated to affect upwards of 26 million individuals worldwide. Following an initial hospitalization for heart failure, approximately 25% of patients are readmitted within the first 30 days of discharge. Repeat heart failure hospitalizations are a major burden on both patients and healthcare systems. To date, there is an absence of non-invasive solutions proven to reduce the risk of re-hospitalization for CHF.

The key feature of the physical examination for assessing the volume status of CHF patients is the JVP, which manifests as a biphasic pulsation along the neck. The height of the JVP relative to the sternal angle is a reflection of right atrial pressure, which increases in response to higher pressures transmitted from the left side of the heart. Pathologic elevation of left sided heart pressures can result in fluid congestion in the lungs, which can cause patients to develop shortness of breath and reduced blood oxygen levels. Although a crucial marker of volume status, accurate identification of the JVP can be challenging for physicians due to its pulsations often being subtle.

The JVPHome is a novel medical device that utilizes machine vision in order to facilitate assessment of jugular venous pressure (JVP) height relative to the sternal angle with the ultimate goal of enabling remote JVP monitoring. The current study aims to evaluate the ability of the JVPHome to enable remote identification of JVP height relative to ultrasound among congestive heart failure (CHF) patients when the device is applied by the study team in the clinic.

The clinical trial started in January 1, 2021 and will continue throughout September 1, 2021.

Among study population are ambulatory CHF outpatients followed at the specialty heart failure clinic at Eastern Health in St. John's, Newfoundland and Labrador, Canada.

The list of inclusion criteria:

  • Age >/= 18 years
  • Congestive heart failure diagnosis receiving ongoing treatment
  • Able to provide informed consent

The contacts and locations are the Eastern Health, St. John's, Newfoundland and Labrador, Canada.

Further details can be found here: https://ichgcp.net/clinical-trials-registry/NCT04807985

Clinical Research News

Próximos ensaios clínicos